Home TMU FAQ Sitemap
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202303137 A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GMXANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients. Atopic Dermatitis SHH Dermatology Chia-Lun Chou 02-6620-2589
N202305029 A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA Ischemic stroke SHH Neurology Lung Chan 02-6620-2589
N202307004 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy Breast Cancer SHH Hematology and Oncology Tsu-Yi Chao 02-6620-2589
N202307012 An Open-Label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis Atopic Dermatitis SHH Dermatology Woan-Ruoh Lee 02-6620-2589
N202312002 A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee 02-6620-2589
N202401013 A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma Melanoma SHH Hematology and Oncology Yao-Yu Hsieh 02-6620-2589
N202402003 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) Nephropathy SHH Nephrology Mai-Szu Wu 02-6620-2589
N202404021 A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors Solid tumors SHH Hematology and Oncology Wei-Hong Cheng 02-6620-2589
N202407071 A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-Conjugated Gamma Delta T-Cell therapy, in Adult Subjects with Relapsed/Refractory CD20 Expressing B-cell Malignancies B-cell Malignancies SHH Hematology and Oncology Yao-Yu Hsieh 02-6620-2589
N202408025 An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-Cell Malignancies B-Cell Malignancies SHH Hematology and Oncology Yao-Yu Hsieh 02-6620-2589
1 2 7 8 9 10 11 12 13 14 15 16 / 16

TOP